Anti-L-selectin antibody therapy does not worsen the postseptic course in a baboon model
2005

Anti-L-selectin Antibody Therapy in Sepsis

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): Heinz R. Redl, Ulrich Martin, Anna Khadem, Linda E. Pelinka, Martijn van Griensven

Primary Institution: Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

Hypothesis

Does anti-L-selectin antibody therapy negatively affect outcomes in a baboon model of sepsis?

Conclusion

Anti-L-selectin therapy did not adversely affect survival or organ function in the baboon sepsis model and improved bacterial clearance.

Supporting Evidence

  • The mortality rate and mean survival time were similar in both treatment groups.
  • Bacterial clearance was significantly improved in the anti-L-selectin group.
  • No major side effects were observed in the anti-L-selectin group.

Takeaway

This study tested a treatment that helps the body fight infections without making things worse, and it found that the treatment worked well in sick baboons.

Methodology

Sixteen baboons were divided into two groups, one receiving anti-L-selectin antibody and the other a placebo, followed by E. coli infusion to induce sepsis.

Potential Biases

Potential bias in the selection of treatment and control groups.

Limitations

The study was conducted in a controlled environment with a specific model that may not fully represent human sepsis.

Participant Demographics

Sixteen adult male Chacma baboons, aged and weight unspecified.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/cc3825

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication